Advertisement

Topics

Biogen and Sobi Company Profile

23:23 EDT 28th March 2017 | BioPortfolio

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.


News Articles [560 Associated News Articles listed on BioPortfolio]

Sobi Seeks New CEO Who Is Around Sweden, Europe As Business Grows

Sobi's outgoing US-based CEO says his extended handover will “maintain continuity” as Sweden's rare disease specialist searches for a successor...    

Sobi - Invitation - Presentation Of Sobi's Q4 And FY 2016 Results

  Life Sciences Jobs   ...

BRIEF-Sobi says CEO Geoffrey McDonough to leave company

STOCKHOLM, Jan 9 (Reuters) - Swedish Orphan Biovitrum AB (Sobi) :

BRIEF-Sobi Q3 EBITA tops forecasts, raises outlook

* Reuters poll: Sobi Q3 ebita was seen at sek 183 million, revenues at 1,139 million

Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting

New Longitudinal Data Show Long-Term Prophylactic Use of ELOCTATE Resulted in Effective Target Joint Resolution and Improved Quality of Life Measures SAN DIEGO–(BUSINESS WIRE)–Biogen (NASD...

Armin Reininger leaves Shire to join Sobi as new head of medical affairs

Biotech firm Sobi have announced the recruitment of Armin Reininger as senior vice president and head…

Swissmedic approves Sobi’s Alprolix to treat haemophilia B

The Swiss Agency for Therapeutic Products, Swissmedic, has approved Sobi’s Alprolix (eftrenonacog alfa) for the treatment of haemophilia B.

First Patient Randomized in a Phase II Study Evaluating the Safety and Efficacy of Anakinra in ...

SobiMedia relationsLinda Holmström, Senior Communications ManagerT: + 46 708 73 40 95+ 46 8 697 31 74linda.holmstrom@sobi.comorInvestor relationsJörgen Winroth, Vice President, Head o...

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

To determine the maximal safe daily dose of BG8962 (rCD4) which can be administered by continuous subcutaneous infusion (CSCI) over 24 hours; to determine the pharmacokinetics of BG8962 wh...

Safety and Tolerability of Repeat Courses of IM Alefacept

Previous Biogen studies have provided experience with the tolerability, immunogenicity, and efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage, experi...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy

Study phase: Phase II Investigational product, dosage, and route of administration: Ibritumomab tiuxetan ("Zevalin) is composed of a murine IgG1 monoclonal antibody (ibritumomab) covalentl...

Companies [31 Associated Companies listed on BioPortfolio]

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare ...

Swedish Orphan Biovitrum AB

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. Sobi have a diversi...

Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the li...

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

More Information about "Biogen and Sobi" on BioPortfolio

We have published hundreds of Biogen and Sobi news stories on BioPortfolio along with dozens of Biogen and Sobi Clinical Trials and PubMed Articles about Biogen and Sobi for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen and Sobi Companies in our database. You can also find out about relevant Biogen and Sobi Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record